5-fluorouracil for epithelial downgrowth after Descemet stripping automated endothelial keratoplasty

Ryan K. Wong, Daniel P. Greene, David R. Shield, Charles G Eberhart, John J. Huang, Aryan Shayegani

Research output: Contribution to journalArticle

Abstract

PURPOSE:: To report the use of intracameral 5-fluorouracil (5-FU) to treat epithelial downgrowth after performing a Descemet-stripping automated endothelial keratoplasty (DSAEK). METHODS:: We describe the case of a 79-year-old woman who underwent a DSAEK for pseudophakic Fuchs endothelial corneal dystrophy. The patient required 2 repeat DSAEKs for graft failure and persistent, visually significant interface haze. Six months after the third and most recent DSAEK, the patient was followed up and found to have a visual acuity of 20/100. On examination, the patient continued to have a persistent interface haze. However, the patient also had a cellular anterior chamber reaction despite the administration of frequent topical corticosteroids, and subtle findings of a translucent, membranous growth over the iris. Argon laser photocoagulation of the area resulted in a whitening response, characteristic of epithelial growth. RESULTS:: Epithelial downgrowth was diagnosed, and intracameral 5-FU was administered. One month after the injection was given, the patient's examination results and vision improved to 20/60. Six months after the single injection, the patient had a clear DSAEK graft without interface haze, a quiet chamber, and 20/30 visual acuity. CONCLUSIONS:: Epithelial downgrowth that occurs after performing a DSAEK can be treated successfully using intracameral 5-FU.

Original languageEnglish (US)
Pages (from-to)1610-1612
Number of pages3
JournalCornea
Volume32
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Descemet Stripping Endothelial Keratoplasty
Fluorouracil
Visual Acuity
Fuchs' Endothelial Dystrophy
Transplants
Topical Administration
Injections
Light Coagulation
Argon
Anterior Chamber
Iris
Growth
Adrenal Cortex Hormones
Lasers

Keywords

  • 5-fluorouracil
  • Descemet-stripping automated endothelial keratoplasty
  • epithelial downgrowth/ingrowth
  • interface haze

ASJC Scopus subject areas

  • Ophthalmology

Cite this

5-fluorouracil for epithelial downgrowth after Descemet stripping automated endothelial keratoplasty. / Wong, Ryan K.; Greene, Daniel P.; Shield, David R.; Eberhart, Charles G; Huang, John J.; Shayegani, Aryan.

In: Cornea, Vol. 32, No. 12, 12.2013, p. 1610-1612.

Research output: Contribution to journalArticle

Wong, Ryan K. ; Greene, Daniel P. ; Shield, David R. ; Eberhart, Charles G ; Huang, John J. ; Shayegani, Aryan. / 5-fluorouracil for epithelial downgrowth after Descemet stripping automated endothelial keratoplasty. In: Cornea. 2013 ; Vol. 32, No. 12. pp. 1610-1612.
@article{0c58b5cd11064564bf398815b3b0aeae,
title = "5-fluorouracil for epithelial downgrowth after Descemet stripping automated endothelial keratoplasty",
abstract = "PURPOSE:: To report the use of intracameral 5-fluorouracil (5-FU) to treat epithelial downgrowth after performing a Descemet-stripping automated endothelial keratoplasty (DSAEK). METHODS:: We describe the case of a 79-year-old woman who underwent a DSAEK for pseudophakic Fuchs endothelial corneal dystrophy. The patient required 2 repeat DSAEKs for graft failure and persistent, visually significant interface haze. Six months after the third and most recent DSAEK, the patient was followed up and found to have a visual acuity of 20/100. On examination, the patient continued to have a persistent interface haze. However, the patient also had a cellular anterior chamber reaction despite the administration of frequent topical corticosteroids, and subtle findings of a translucent, membranous growth over the iris. Argon laser photocoagulation of the area resulted in a whitening response, characteristic of epithelial growth. RESULTS:: Epithelial downgrowth was diagnosed, and intracameral 5-FU was administered. One month after the injection was given, the patient's examination results and vision improved to 20/60. Six months after the single injection, the patient had a clear DSAEK graft without interface haze, a quiet chamber, and 20/30 visual acuity. CONCLUSIONS:: Epithelial downgrowth that occurs after performing a DSAEK can be treated successfully using intracameral 5-FU.",
keywords = "5-fluorouracil, Descemet-stripping automated endothelial keratoplasty, epithelial downgrowth/ingrowth, interface haze",
author = "Wong, {Ryan K.} and Greene, {Daniel P.} and Shield, {David R.} and Eberhart, {Charles G} and Huang, {John J.} and Aryan Shayegani",
year = "2013",
month = "12",
doi = "10.1097/ICO.0b013e3182a9fc85",
language = "English (US)",
volume = "32",
pages = "1610--1612",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - 5-fluorouracil for epithelial downgrowth after Descemet stripping automated endothelial keratoplasty

AU - Wong, Ryan K.

AU - Greene, Daniel P.

AU - Shield, David R.

AU - Eberhart, Charles G

AU - Huang, John J.

AU - Shayegani, Aryan

PY - 2013/12

Y1 - 2013/12

N2 - PURPOSE:: To report the use of intracameral 5-fluorouracil (5-FU) to treat epithelial downgrowth after performing a Descemet-stripping automated endothelial keratoplasty (DSAEK). METHODS:: We describe the case of a 79-year-old woman who underwent a DSAEK for pseudophakic Fuchs endothelial corneal dystrophy. The patient required 2 repeat DSAEKs for graft failure and persistent, visually significant interface haze. Six months after the third and most recent DSAEK, the patient was followed up and found to have a visual acuity of 20/100. On examination, the patient continued to have a persistent interface haze. However, the patient also had a cellular anterior chamber reaction despite the administration of frequent topical corticosteroids, and subtle findings of a translucent, membranous growth over the iris. Argon laser photocoagulation of the area resulted in a whitening response, characteristic of epithelial growth. RESULTS:: Epithelial downgrowth was diagnosed, and intracameral 5-FU was administered. One month after the injection was given, the patient's examination results and vision improved to 20/60. Six months after the single injection, the patient had a clear DSAEK graft without interface haze, a quiet chamber, and 20/30 visual acuity. CONCLUSIONS:: Epithelial downgrowth that occurs after performing a DSAEK can be treated successfully using intracameral 5-FU.

AB - PURPOSE:: To report the use of intracameral 5-fluorouracil (5-FU) to treat epithelial downgrowth after performing a Descemet-stripping automated endothelial keratoplasty (DSAEK). METHODS:: We describe the case of a 79-year-old woman who underwent a DSAEK for pseudophakic Fuchs endothelial corneal dystrophy. The patient required 2 repeat DSAEKs for graft failure and persistent, visually significant interface haze. Six months after the third and most recent DSAEK, the patient was followed up and found to have a visual acuity of 20/100. On examination, the patient continued to have a persistent interface haze. However, the patient also had a cellular anterior chamber reaction despite the administration of frequent topical corticosteroids, and subtle findings of a translucent, membranous growth over the iris. Argon laser photocoagulation of the area resulted in a whitening response, characteristic of epithelial growth. RESULTS:: Epithelial downgrowth was diagnosed, and intracameral 5-FU was administered. One month after the injection was given, the patient's examination results and vision improved to 20/60. Six months after the single injection, the patient had a clear DSAEK graft without interface haze, a quiet chamber, and 20/30 visual acuity. CONCLUSIONS:: Epithelial downgrowth that occurs after performing a DSAEK can be treated successfully using intracameral 5-FU.

KW - 5-fluorouracil

KW - Descemet-stripping automated endothelial keratoplasty

KW - epithelial downgrowth/ingrowth

KW - interface haze

UR - http://www.scopus.com/inward/record.url?scp=84888133872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888133872&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3182a9fc85

DO - 10.1097/ICO.0b013e3182a9fc85

M3 - Article

C2 - 24113368

AN - SCOPUS:84888133872

VL - 32

SP - 1610

EP - 1612

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 12

ER -